果公司在第四季度收益下滑后降级至持有. Apellis downgraded to hold after beating Q4 earnings.

由于第四季度的收益比预期好,一些分析师将Apellis Pharmaceuticals (APLS) 的评级降至"持有",尽管潜在的收购引发了股价投机. Apellis Pharmaceuticals (APLS) was downgraded to "hold" by several analysts following better-than-expected Q4 earnings, though a potential acquisition has driven share price speculation. 尽管利估计超过预期, 但该股面临监管障碍, 分析师的平均目标为33美元. Despite beating earnings estimates, the stock faces regulatory hurdles, with an average analyst target of $33.